Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening

Grace Hui Min Wu, Anssi Auvinen, Liisa Määttänen, Teuvo L J Tammela, Ulf Hãkan Stenman, Matti Hakama, Amy Ming Fang Yen, Hsiu Hsi Chen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

As with wide-spread use of prostate cancer (Pca) screening with prostate-specific antigen testing, overdetection has increasingly gained attention. The authors aimed to estimate absolute risk of overdetection (RO) in Pca screening with various interscreening intervals and ages at start of screening. We estimated age-specific preclinical incidence rates (per 100,000 person-years) for progressive cancer (from 128 for age group 55-58 years to 774 for age group 67-71 years) and nonprogressive cancer (from 40 for age group 55-58 years to 66 for age group 67-71 years), the mean sojourn time (7.72 years) and the sensitivity (42.8% at first screen and 59.8% at the second screen) by using a multistep epidemiological model with data from the Finnish randomized controlled trial. The overall number of screens for overdetection (NSO) was 29 (95% confidence interval (CI): 18, 48) for screenees aged 55-67 years, equivalent to 3.4 (95% CI: 2.1, 5.7) overdetected Pcas per 100 screenees. The NSO decreased from 63 (95% CI: 37, 109) at the first screen to 29 (95% CI: 18, 48) at the third screen and from 43 (95% CI: 36, 52) for age 55 years to 25 (95% CI: 8, 75) at age 67 years at the first screen. In conclusion, around 3.4 cases for every 100 screened men would be overdetected during three screen rounds (∼ 13 years of follow-up) in the Finnish randomized controlled trial. Elucidating the absolute RO under various scenarios makes contribution for evaluating the benefit and harm of Pca screening.

Original languageEnglish
Pages (from-to)1367-1375
Number of pages9
JournalInternational Journal of Cancer
Volume131
Issue number6
DOIs
Publication statusPublished - Sep 15 2012

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Confidence Intervals
Age Groups
Randomized Controlled Trials
Prostate-Specific Antigen
Medical Overuse
Neoplasms
Incidence

Keywords

  • mass screening
  • prostate-specific antigen
  • prostatic neoplasms
  • randomized controlled trial
  • sensitivity and specificity
  • stochastic processes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wu, G. H. M., Auvinen, A., Määttänen, L., Tammela, T. L. J., Stenman, U. H., Hakama, M., ... Chen, H. H. (2012). Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. International Journal of Cancer, 131(6), 1367-1375. https://doi.org/10.1002/ijc.27340

Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. / Wu, Grace Hui Min; Auvinen, Anssi; Määttänen, Liisa; Tammela, Teuvo L J; Stenman, Ulf Hãkan; Hakama, Matti; Yen, Amy Ming Fang; Chen, Hsiu Hsi.

In: International Journal of Cancer, Vol. 131, No. 6, 15.09.2012, p. 1367-1375.

Research output: Contribution to journalArticle

Wu, GHM, Auvinen, A, Määttänen, L, Tammela, TLJ, Stenman, UH, Hakama, M, Yen, AMF & Chen, HH 2012, 'Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening', International Journal of Cancer, vol. 131, no. 6, pp. 1367-1375. https://doi.org/10.1002/ijc.27340
Wu, Grace Hui Min ; Auvinen, Anssi ; Määttänen, Liisa ; Tammela, Teuvo L J ; Stenman, Ulf Hãkan ; Hakama, Matti ; Yen, Amy Ming Fang ; Chen, Hsiu Hsi. / Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. In: International Journal of Cancer. 2012 ; Vol. 131, No. 6. pp. 1367-1375.
@article{ad1bce15c8934e48b4299e82b0558730,
title = "Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening",
abstract = "As with wide-spread use of prostate cancer (Pca) screening with prostate-specific antigen testing, overdetection has increasingly gained attention. The authors aimed to estimate absolute risk of overdetection (RO) in Pca screening with various interscreening intervals and ages at start of screening. We estimated age-specific preclinical incidence rates (per 100,000 person-years) for progressive cancer (from 128 for age group 55-58 years to 774 for age group 67-71 years) and nonprogressive cancer (from 40 for age group 55-58 years to 66 for age group 67-71 years), the mean sojourn time (7.72 years) and the sensitivity (42.8{\%} at first screen and 59.8{\%} at the second screen) by using a multistep epidemiological model with data from the Finnish randomized controlled trial. The overall number of screens for overdetection (NSO) was 29 (95{\%} confidence interval (CI): 18, 48) for screenees aged 55-67 years, equivalent to 3.4 (95{\%} CI: 2.1, 5.7) overdetected Pcas per 100 screenees. The NSO decreased from 63 (95{\%} CI: 37, 109) at the first screen to 29 (95{\%} CI: 18, 48) at the third screen and from 43 (95{\%} CI: 36, 52) for age 55 years to 25 (95{\%} CI: 8, 75) at age 67 years at the first screen. In conclusion, around 3.4 cases for every 100 screened men would be overdetected during three screen rounds (∼ 13 years of follow-up) in the Finnish randomized controlled trial. Elucidating the absolute RO under various scenarios makes contribution for evaluating the benefit and harm of Pca screening.",
keywords = "mass screening, prostate-specific antigen, prostatic neoplasms, randomized controlled trial, sensitivity and specificity, stochastic processes",
author = "Wu, {Grace Hui Min} and Anssi Auvinen and Liisa M{\"a}{\"a}tt{\"a}nen and Tammela, {Teuvo L J} and Stenman, {Ulf H{\~a}kan} and Matti Hakama and Yen, {Amy Ming Fang} and Chen, {Hsiu Hsi}",
year = "2012",
month = "9",
day = "15",
doi = "10.1002/ijc.27340",
language = "English",
volume = "131",
pages = "1367--1375",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening

AU - Wu, Grace Hui Min

AU - Auvinen, Anssi

AU - Määttänen, Liisa

AU - Tammela, Teuvo L J

AU - Stenman, Ulf Hãkan

AU - Hakama, Matti

AU - Yen, Amy Ming Fang

AU - Chen, Hsiu Hsi

PY - 2012/9/15

Y1 - 2012/9/15

N2 - As with wide-spread use of prostate cancer (Pca) screening with prostate-specific antigen testing, overdetection has increasingly gained attention. The authors aimed to estimate absolute risk of overdetection (RO) in Pca screening with various interscreening intervals and ages at start of screening. We estimated age-specific preclinical incidence rates (per 100,000 person-years) for progressive cancer (from 128 for age group 55-58 years to 774 for age group 67-71 years) and nonprogressive cancer (from 40 for age group 55-58 years to 66 for age group 67-71 years), the mean sojourn time (7.72 years) and the sensitivity (42.8% at first screen and 59.8% at the second screen) by using a multistep epidemiological model with data from the Finnish randomized controlled trial. The overall number of screens for overdetection (NSO) was 29 (95% confidence interval (CI): 18, 48) for screenees aged 55-67 years, equivalent to 3.4 (95% CI: 2.1, 5.7) overdetected Pcas per 100 screenees. The NSO decreased from 63 (95% CI: 37, 109) at the first screen to 29 (95% CI: 18, 48) at the third screen and from 43 (95% CI: 36, 52) for age 55 years to 25 (95% CI: 8, 75) at age 67 years at the first screen. In conclusion, around 3.4 cases for every 100 screened men would be overdetected during three screen rounds (∼ 13 years of follow-up) in the Finnish randomized controlled trial. Elucidating the absolute RO under various scenarios makes contribution for evaluating the benefit and harm of Pca screening.

AB - As with wide-spread use of prostate cancer (Pca) screening with prostate-specific antigen testing, overdetection has increasingly gained attention. The authors aimed to estimate absolute risk of overdetection (RO) in Pca screening with various interscreening intervals and ages at start of screening. We estimated age-specific preclinical incidence rates (per 100,000 person-years) for progressive cancer (from 128 for age group 55-58 years to 774 for age group 67-71 years) and nonprogressive cancer (from 40 for age group 55-58 years to 66 for age group 67-71 years), the mean sojourn time (7.72 years) and the sensitivity (42.8% at first screen and 59.8% at the second screen) by using a multistep epidemiological model with data from the Finnish randomized controlled trial. The overall number of screens for overdetection (NSO) was 29 (95% confidence interval (CI): 18, 48) for screenees aged 55-67 years, equivalent to 3.4 (95% CI: 2.1, 5.7) overdetected Pcas per 100 screenees. The NSO decreased from 63 (95% CI: 37, 109) at the first screen to 29 (95% CI: 18, 48) at the third screen and from 43 (95% CI: 36, 52) for age 55 years to 25 (95% CI: 8, 75) at age 67 years at the first screen. In conclusion, around 3.4 cases for every 100 screened men would be overdetected during three screen rounds (∼ 13 years of follow-up) in the Finnish randomized controlled trial. Elucidating the absolute RO under various scenarios makes contribution for evaluating the benefit and harm of Pca screening.

KW - mass screening

KW - prostate-specific antigen

KW - prostatic neoplasms

KW - randomized controlled trial

KW - sensitivity and specificity

KW - stochastic processes

UR - http://www.scopus.com/inward/record.url?scp=84864126860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864126860&partnerID=8YFLogxK

U2 - 10.1002/ijc.27340

DO - 10.1002/ijc.27340

M3 - Article

VL - 131

SP - 1367

EP - 1375

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -